相似文献
1
Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades.
Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):580-597. doi: 10.1016/j.clml.2021.05.016. Epub 2021 May 29.
2
Incorporating newer agents in the treatment of acute myeloid leukemia.
Leuk Res. 2018 Nov;74:113-120. doi: 10.1016/j.leukres.2018.10.008. Epub 2018 Oct 19.
3
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Cancer. 2021 Apr 15;127(8):1186-1207. doi: 10.1002/cncr.33477. Epub 2021 Mar 18.
4
Management of Acute Myeloid Leukemia (AML) in Older Patients.
Curr Oncol Rep. 2020 Jul 28;22(10):103. doi: 10.1007/s11912-020-00964-1.
5
Treating acute myeloid leukemia in the modern era: A primer.
Cancer. 2020 Nov 1;126(21):4668-4677. doi: 10.1002/cncr.32904. Epub 2020 Aug 7.
6
Acute myeloid leukemia in older adults.
Int J Hematol. 2012 Aug;96(2):186-93. doi: 10.1007/s12185-012-1137-3. Epub 2012 Jul 13.
7
Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Mol Diagn Ther. 2020 Feb;24(1):1-13. doi: 10.1007/s40291-019-00443-9.
8
Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment patterns and outcomes.
Future Oncol. 2023 Aug;19(24):1677-1693. doi: 10.2217/fon-2022-0786. Epub 2023 Jun 22.
9
Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia.
Pharm Res. 2019 Jun 24;36(9):125. doi: 10.1007/s11095-019-2654-z.
10
Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches.
Biochem Pharmacol. 2023 Sep;215:115705. doi: 10.1016/j.bcp.2023.115705. Epub 2023 Jul 31.
引用本文的文献
1
Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines.
Sci Rep. 2025 Jun 3;15(1):19431. doi: 10.1038/s41598-025-03242-x.
2
Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions.
Int J Mol Sci. 2025 May 10;26(10):4571. doi: 10.3390/ijms26104571.
3
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements.
Leukemia. 2025 May 9. doi: 10.1038/s41375-025-02634-2.
4
A Simple Machine Learning-Based Quantitative Structure-Activity Relationship Model for Predicting pIC Inhibition Values of FLT3 Tyrosine Kinase.
Pharmaceuticals (Basel). 2025 Jan 14;18(1):96. doi: 10.3390/ph18010096.
5
Advancing Chimeric Antigen Receptor T-Cell Therapy for Acute Myeloid Leukemia: Current Limitations and Emerging Strategies.
Pharmaceuticals (Basel). 2024 Dec 4;17(12):1629. doi: 10.3390/ph17121629.
6
Csec-net: a novel deep features fusion and entropy-controlled firefly feature selection framework for leukemia classification.
Health Inf Sci Syst. 2024 Dec 28;13(1):9. doi: 10.1007/s13755-024-00327-1. eCollection 2025 Dec.
7
Acute myeloid leukemia management and research in 2025.
CA Cancer J Clin. 2025 Jan-Feb;75(1):46-67. doi: 10.3322/caac.21873. Epub 2024 Dec 10.
8
Current status and research directions in acute myeloid leukemia.
Blood Cancer J. 2024 Sep 19;14(1):163. doi: 10.1038/s41408-024-01143-2.
9
Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines.
Res Sq. 2024 Aug 26:rs.3.rs-4159724. doi: 10.21203/rs.3.rs-4159724/v1.
10
Utilization of allogeneic hematopoietic stem cell transplantation among patients with newly diagnosed acute myeloid leukemia in California: a population-based linked dataset study.
Haematologica. 2025 Feb 1;110(2):368-377. doi: 10.3324/haematol.2024.285648.
本文引用的文献
1
Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia.
Blood Cancer Discov. 2020 Aug 11;1(2):134-145. doi: 10.1158/2643-3230.BCD-20-0007. eCollection 2020 Sep.
2
Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape.
J Clin Oncol. 2021 Aug 10;39(23):2535-2538. doi: 10.1200/JCO.21.00067. Epub 2021 May 27.
3
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
J Clin Oncol. 2021 Sep 1;39(25):2768-2778. doi: 10.1200/JCO.20.03736. Epub 2021 May 27.
4
De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017.
Cancer. 2021 Jun 15;127(12):2049-2061. doi: 10.1002/cncr.33458. Epub 2021 Apr 5.
5
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Cancer. 2021 Apr 15;127(8):1186-1207. doi: 10.1002/cncr.33477. Epub 2021 Mar 18.
6
Mayo Clinic experience with 1123 adults with acute myeloid leukemia.
Blood Cancer J. 2021 Mar 2;11(3):46. doi: 10.1038/s41408-021-00435-1.
7
Acute myeloid leukemia: current progress and future directions.
Blood Cancer J. 2021 Feb 22;11(2):41. doi: 10.1038/s41408-021-00425-3.
8
Eprenetapopt Plus Azacitidine in -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).
J Clin Oncol. 2021 May 10;39(14):1575-1583. doi: 10.1200/JCO.20.02342. Epub 2021 Feb 18.
9
Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of -ITD in Mutated AML, Irrespectively of -ITD Allelic Burden.
Cancers (Basel). 2020 Dec 24;13(1):34. doi: 10.3390/cancers13010034.
10
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444.
Zotero 插件